Mielóma multiplex: vizsgálatok itt: Hollandia
32 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
- Where
- Dordrecht, Nijmegen
- Életkor
- 18 év and over
- People
- 410 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT05730036 · EU 2022-501396-62-00 - 1. fázisTaking peopleA Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- Where
- Amsterdam, Groningen
- Életkor
- 18 év and over
- People
- 317 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT05137054 · EU 2023-506247-42-00 - 2. fázisTaking peopleA study with new methods to monitor newly diagnosed multiple myeloma in participants being treated with a new treatment combination - TAURUS
- Where
- Amsterdam, Arnhem, Breda, Groningen, Hoorn Nh, Rotterdam
- Életkor
- 18 év and over
- People
- 240 worldwide
- Run by
- European Myeloma Network B.V.
See details and how to joinNCT06189833 · EU 2023-505221-14-00 - 3. fázisTaking peopleA Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- Where
- Breda, Hoofddorp, Nijmegen, Rotterdam
- Életkor
- 18 év and over
- People
- 915 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT07222761 · EU 2024-519504-27-00 - 2. fázisTaking peopleA Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Amsterdam, Utrecht
- Életkor
- 18 év and over
- People
- 510 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT04634552 · EU 2023-504581-29-00 - 4. fázisTaking peopleA Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Where
- Amsterdam, Groningen, Rotterdam, Utrecht
- Életkor
- 18 év and over
- People
- 295 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05201781 · EU 2023-505530-10-00 - 3. fázisTaking peopleA Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Where
- Amsterdam, Apeldoorn, Delft, Geleen, Nieuwegein
- Életkor
- 18 év and over
- People
- 1590 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05552222 · EU 2023-503442-30-00 - 1. fázisTaking peopleA Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
- Where
- Amsterdam, Groningen, Utrecht
- Életkor
- 18 év and over
- People
- 180 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05652335 · EU 2023-503679-12-00 - 3. fázisTaking peopleA Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Amsterdam, Groningen, Nieuwegein, Nijmegen, Rotterdam, 's-Gravenhage
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07258511 · EU 2025-522007-18-00 - 3. fázisTaking peopleA Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
- Where
- Eindhoven, Groningen, Nieuwegein, Sittard-Geleen, Utrecht
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07665450 - 3. fázisTaking peopleA Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Where
- Amsterdam, Maastricht, Nijmegen, Utrecht
- Életkor
- 18 év and over
- People
- 440 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00 - 3. fázisTaking peopleA Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Where
- Dordrecht, Groningen
- Életkor
- 18 év and over
- People
- 1060 worldwide
- Run by
- Pfizer
See details and how to joinNCT05623020 · EU 2024-514139-50-00 - 3. fázisTaking peopleA Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
- Where
- Eindhoven, Geleen, Groningen, Nieuwegein, Nijmegen, Utrecht
- Életkor
- 18 év and over
- People
- 423 worldwide
- Run by
- Janssen Cilag International
See details and how to join2026-526654-14-01 · EU 2026-526654-14-01 - 3. fázisTaking peopleA Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- Where
- Amsterdam, Nieuwegein
- Életkor
- 18 év and over
- People
- 183 worldwide
- Run by
- Takeda
See details and how to joinNCT06980480 · EU 2024-518420-80-00 - 2. fázisTaking peopleA Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
- Where
- Amsterdam, Dordrecht, Rotterdam
- Életkor
- 18 év and over
- People
- 210 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06500884 · EU 2023-506260-14-00 - 1. fázisTaking peopleA Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
- Where
- Amsterdam, Groningen, Utrecht
- Életkor
- 18 év and over
- People
- 276 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06768489 · EU 2024-515316-44-00 - 3. fázisTaking peopleA long-term follow-up study for patients treated with Galapagos CAR T cell therapies
- Where
- Amsterdam, Leiden, Maastricht, Rotterdam
- Életkor
- 18 év and over
- People
- 309 worldwide
- Run by
- Lakefront Biotherapeutics
See details and how to join2023-510173-34-00 · EU 2023-510173-34-00 - 1/2. fázisTaking people[68Ga]Ga-PentixaFor positron emission tomography for improved risk and disease assessment in myeloma
- Where
- Amsterdam
- Életkor
- 18 év and over
- People
- 90 worldwide
- Run by
- University Of Antwerp
See details and how to join2022-501811-14-00 · EU 2022-501811-14-00 - 2. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- Where
- Amersfoort, Hoofddorp, 's-Gravenhage
- Életkor
- 18 év and over
- People
- 200 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07227311 · EU 2025-523117-28-00 - 3. fázisTaking peopleA Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- Where
- Maastricht, Rotterdam
- Életkor
- 18 év and over
- People
- 893 worldwide
- Run by
- Pfizer
See details and how to joinNCT05020236 · EU 2023-509208-14-00 - 3. fázisTaking peopleMagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Where
- Dordrecht, Maastricht, Rotterdam
- Életkor
- 18 év and over
- People
- 492 worldwide
- Run by
- Pfizer
See details and how to joinNCT06152575 · EU 2023-507871-23-00 - 2. fázisTaking peopleDRUP trial
- Where
- Alkmaar, Almelo, Amersfoort, Amsterdam, Apeldoorn, Arnhem, Breda, Delft, Deventer, Drachten, Ede Gld, Eindhoven, Gorinchem, Groningen, Heerlen, Hilversum, Hoofddorp, Hoogeveen, Leeuwarden, Leiden, Leidschendam, Maastricht, Nijmegen, Roosendaal, Rotterdam, Schiedam, 's-Gravenhage, Tilburg, Utrecht, Venlo, Zwolle
- Életkor
- 18 év and over
- People
- 3000
- Run by
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
See details and how to joinNCT02925234 · EU 2023-509152-33-00 - 1/2. fázisTaking peopleA Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- Where
- Amsterdam, Groningen, Nijmegen, Rotterdam, Utrecht
- Életkor
- 18 év and over
- People
- 220 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06292780 · EU 2023-507809-34-00 - 1. fázisTaking peopleLong-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies
- Where
- Amsterdam
- People
- 7 worldwide
- Run by
- USWM Ct LLC
See details and how to join2024-513033-21-00 · EU 2024-513033-21-00 - 2. fázisTaking peopleA multi-center, open-label, phase 2 study of Elranatamab in patients with high-risk smoldering multiple myeloma
- Where
- Maastricht, Nieuwegein, Rotterdam
- Életkor
- 18 év and over
- People
- 105 worldwide
- Run by
- European Myeloma Network B.V.
See details and how to join2023-505775-70-00 · EU 2023-505775-70-00